{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:51:27Z","timestamp":1790905887512,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Duchenne muscular dystrophy (DMD) is an X-linked disorder caused by DMD gene mutations, leading to muscle wasting due to dystrophin deficiency. Current treatment with corticosteroids like prednisone shows benefits but lacks clarity on optimal dosing regimens. This systematic review and meta-analysis aim to determine the efficacy and safety of daily versus intermittent prednisone dosing in DMD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a systematic search of PubMed, Google Scholar, Embase, and Scopus databases to identify studies comparing daily versus intermittent prednisone in DMD treatment. The study protocol was registered with PROSPERO (CRD42024549050).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After the systematic search, 6 trials were included in the pooled analysis. Intermittent prednisone was associated with a higher prevalence of cushingoid appearance (RR: 1.72; 95% CI: 1.17 to 2.51;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.005), excessive hair growth (RR: 1.56; 95% CI: 1.08 to 2.24;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.02), and hypertension (RR: 3.42; 95% CI: 1.87 to 6.25;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). In contrast, there were no statistically significant differences between daily versus intermittent prednisone in terms of forced vital capacity (FVC), blood pressure, loss of ambulation, weight changes, weight gain, bone fracture, behavioral changes, and DEXA lumbar spine Z-scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>No significant differences in efficacy outcomes regimens were observed. However, intermittent prednisone was associated with a higher prevalence of certain adverse effects, such as cushingoid appearance, excessive hair growth, and hypertension. These findings provide valuable insights for clinicians when choosing treatment strategies and highlight the need for personalized approaches to minimize side effects while maintaining efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000003049","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T14:02:09Z","timestamp":1740578529000},"page":"1637-1645","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Comparing intermittent and daily prednisone in duchenne muscular dystrophy: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"87","author":[{"given":"Eeshal","family":"Zulfiqar","sequence":"first","affiliation":[{"name":"Department of Medicine, Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hurjkaliani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahood Ahmed","family":"Umar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ziauddin Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shahzad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeba","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quareeha","family":"Tahir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ziauddin Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Nizami","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bariha","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Abid","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fazaia Ruth Pfau Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniqa","family":"Baloch","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Shafaat","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Medicine, Bahria University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehwish","family":"Rabbani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marhaba","family":"Fatima","sequence":"additional","affiliation":[{"name":"Department of Medicine, People\u2019s University of Medical and Health Sciences for Women, Nawabshah, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Omar","family":"Larik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow International Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hasanain","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Anjum","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Bhattarai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Manipal College of Medical Sciences, Pokhara, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"R1-20250422","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250422","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/hmg\/ddad173","article-title":"Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models","volume":"33","author":"Liu","year":"2024","journal-title":"Hum Mol Genet"},{"key":"R3-20250422","first-page":"CD003725","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-20250422","doi-asserted-by":"crossref","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne muscular dystrophy: from diagnosis to therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules"},{"key":"R5-20250422","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"R6-20250422","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.pmr.2012.08.003","article-title":"Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy","volume":"23","author":"Hoffman","year":"2012","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"R7-20250422","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R9-20250422","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R10-20250422","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R11-20250422","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"key":"R12-20250422","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"Jama"},{"key":"R13-20250422","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archneur.1991.00530180027012","article-title":"A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy","volume":"48","author":"Fenichel","year":"1991","journal-title":"Arch Neurol"},{"key":"R14-20250422","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R15-20250422","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.braindev.2016.04.001","article-title":"Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan","volume":"38","author":"Goto","year":"2016","journal-title":"Brain Dev"},{"key":"R16-20250422","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mus.27428","article-title":"Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: a randomized, open-label trial","volume":"65","author":"Kochar","year":"2022","journal-title":"Muscle Nerve"},{"key":"R17-20250422","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of Duchenne and Becker muscular dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"key":"R18-20250422","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"R19-20250422","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"R20-20250422","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.nmd.2015.07.009","article-title":"Benefits of glucocorticoids in non-ambulant boys\/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test","volume":"25","author":"Pane","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"R21-20250422","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.nmd.2013.06.001","article-title":"Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study","volume":"23","author":"Mazzone","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"R22-20250422","doi-asserted-by":"crossref","first-page":"e0113999","DOI":"10.1371\/journal.pone.0113999","article-title":"Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne muscular dystrophy: an observational multicenter trial","volume":"10","author":"Seferian","year":"2015","journal-title":"PLoS One"},{"key":"R23-20250422","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1212\/01.wnl.0000489553.99227.18","article-title":"Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development subcommittee of the american academy of neurology","volume":"87","author":"Topaloglu","year":"2016","journal-title":"Neurology"},{"key":"R24-20250422","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"R25-20250422","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JND-221575","article-title":"Functional and clinical outcomes associated with steroid treatment among non-ambulatory patients with Duchenne muscular dystrophy1","volume":"10","author":"Mcdonald","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"R26-20250422","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"key":"R27-20250422","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","article-title":"The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle Nerve"},{"key":"R28-20250422","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1183\/09031936.00127712","article-title":"Sniff nasal inspiratory pressure in the longitudinal assessment of young Duchenne muscular dystrophy children","volume":"42","author":"N\u00e8ve","year":"2013","journal-title":"Eur Respir J"},{"key":"R29-20250422","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00198-003-1443-y","article-title":"Bone mineral density and bone metabolism in Duchenne muscular dystrophy","volume":"14","author":"Bianchi","year":"2003","journal-title":"Osteoporos Int"},{"key":"R31-20250422","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archneur.62.1.128","article-title":"Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial","volume":"62","author":"Beenakker","year":"2005","journal-title":"Arch Neurol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:01:29Z","timestamp":1745298089000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003049","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"2024-08-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}